First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

NCT04360434 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloid Transthyretin Cardiomyopathy

Interventions

DRUG: NI006
DRUG: Placebo

Sponsor

Neurimmune AG